1. Red-hot biotechs to take spotlight at ASH virtual meeting — Moderna's 3-month data raise hopes for COVID-19 vaccine durability — BioNTech founder vaults into world's 500 richest — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Humira lifts AbbVie’s first-quarter results

Discussion in 'AbbVie' started by anonymous, Apr 26, 2018 at 10:59 AM.

  1. anonymous

    anonymous Guest

    AbbVie’s first quarter results topped analyst consensus both on earnings and sales front, driven by double-digit sales growth from Humira, Imbruvica, and HCV. Sales improved 21.4% to $7.9 billion, while adjusted earnings came in at $1.87, up 46%. The company also has decided to buyback shares to the tune of $7.5 billion, as part of the $10 billion share repurchase program announced last quarter.
    Humira’s sales rose 14.4% to $4.7 billion. It’s worth noting that the blockbuster drug brings in nearly 60% of AbbVie’s sales. The company needs to reduce its dependence on the anti-inflammatory drug, diversifying its product pipeline.
    https://news.alphastreet.com/abbvies-first-quarter-results-top-estimates-raises-outlook/
     

  2. anonymous

    anonymous Guest

    It seems as if AbbVie's solution to every business challenge is a Humira price increase in the United States. Seems to me that will be hard to sustain over time but it has worked well so far.
     
  3. anonymous

    anonymous Guest

    Not true. Humira price can easily increase another 30-40% with zero impact on sales. Lets milk this cow as long as we can. Thankfully management understands this and will act accordingly. Wall Street also knows this and has strong BUY ratings for ABBV.
     
  4. anonymous

    anonymous Guest

    Wall street also knows we are ready to tank. SELL NOW !
     
  5. anonymous

    anonymous Guest

    You can't argue with success!
     
  6. anonymous

    anonymous Guest

    Goodbye Humira. Trump's announcement at 2pm today seems likely to curb the company's ability to provide significant rebates, at least in some channels. This will no doubt impact future contracting, possibly even current contracts. It will also take steps to accelerate biosimilar approvals and somehow encourage biosimilar uptake, meaning that Humira will likely face competition much more quickly than anticipated. Most importantly, the increased attention on these issues by Trump will constrain the company's ability to continually raise prices. Better get those resumes updated.
     
  7. anonymous

    anonymous Guest

    Trump won't do nuffin.
     
  8. anonymous

    anonymous Guest

    Think again. Humira is apparently at the top of President Trump's list when he and Secretary Azar ticked off their priorities today. Everything on table. HHS policy changes to limit rebates, more transparency around price increases, requiring the list price be included in drug ads, accelerating biosimilar approvals, and putting limitations on patents. Azar explicitly mentioned all of those in WH Press Conference.
     
  9. anonymous

    anonymous Guest

    Trump will do absolutely nothing. Its all a game and Ricks a player. Donald sold Rick his Multi Million dollar Condo @ Trump Towers. Patent law and decisions are already etched in stone. Humira is good until 2022.
     
  10. anonymous

    anonymous Guest

    Then in 2022 its lights out !!!!!!!!!!!!!
     
  11. anonymous

    anonymous Guest

    LTFOL .. Sad but Sooooo True !!!!!
     
  12. anonymous

    anonymous Guest

    Almost ever biotech closed higher than abbv today
     
  13. anonymous

    anonymous Guest

    LOOK YOU F'ING ASSHOLES HUMIRA IS THE GOLD STANDARD!!!!!!!? STOP POSTING BS!!!!!!

    RICK CAN JACK UP PRICE 50% !!!!!!.!


    NO LAYOFFS !!!!!!I
     
  14. anonymous

    anonymous Guest

    If you think there won't be a spotlight on AbbVie's pricing of Humira going forward, you need to wake up. Government oversight on AbbVie will escalate, especially if the Democrats take the House. It may not provide legal means to block price increases, but it will certainly make it a very thorny PR issue for the company. The glory days are over. AbbVie can't keep compensating for failures elsewhere with US price increases.
     
  15. anonymous

    anonymous Guest

    Thats a FACT Jack !
     
  16. anonymous

    anonymous Guest

    There will be price sensitivity based on Trump's actions which will take time to implement. Also, don't forget that Democrats may win a majority in the House of Representatives and have subpoena power. Look for expansive inquiries into drug pricing and opiods. CEOs with their right hands up testifying after dying patients or family members of dead people make for bad PR and will no doubt have chilling impact on prices.
     
  17. anonymous

    anonymous Guest

    That's a fact Jack !
     
  18. anonymous

    anonymous Guest

    Trump has no allegiance to anyone or any principled points of view other than he thinks drug prices are too high. If public opinion turns on us, so will he.
     
  19. anonymous

    anonymous Guest

    LMAO ! Like drug prices aren't too high now ?? You must be rank & file sales ?? We need to cut drug prices by at least 50% or everyone should go to Canada and buy them at 75% less than US market. BTW Humira is got to be cut by at least 20%.
     
  20. anonymous

    anonymous Guest

    The above is TOTAL BS !!!!!!! Humira price must drop at least 25%